Company intelligence / Profile preview
Proterris
Boston, Massachusetts, United Statesproterris.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Proterris is advancing inhaled carbon monoxide (iCO) in a Phase 2 trial for delayed graft function in kidney transplant recipients, with preclinical programs in graft rejection and other indications leveraging CO-releasing molecules (CORMs).
- Therapeutic areas
- ImmunologyNephrologyCardiovascularPulmonologyGastroenterology
- Modalities
- Small molecule drugBiological products
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
NIH (National Institutes of Health)
Beyond the preview
Go deeper on Proterris.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proterris.